Ixmyelocel-T

Summary

Ixmyelocel-T (CHEMBL2108733) is a phase-3 clinical-stage cell; indicated across 4 conditions including osteonecrosis and ischemic disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Cell
• Indications: 4 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108733
Name	Ixmyelocel-T
Type	Cell
Max phase	3

Also known as: Ixmyelocel-t, IXMYELOCEL-T

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
osteonecrosis	3	MONDO:0005380	EFO:0004259
ischemic disease	3	MONDO:0005053	EFO:0000556
peripheral arterial disease	2	MONDO:0005386	EFO:0004265
dilated cardiomyopathy	2	MONDO:0005021	EFO:0000407

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	4
PHASE3	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00505219	PHASE3	COMPLETED	Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head
NCT01483898	PHASE3	COMPLETED	An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)
NCT00468000	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia
NCT00765518	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
NCT01020968	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
NCT01616953	PHASE1/PHASE2	COMPLETED	Cell Therapy for Craniofacial Bone Defects
NCT01670981	PHASE2	COMPLETED	An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).